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Abstract
Background: Antibiotic resistance is a global problem, but the relationship between antibiotic use and resistance
development and decay is not well understood. This knowledge is best provided by prospective studies, but to be
useful they must be both conducted and reported well. Little is known about the reporting quality of these studies.
This study aimed to assess the quality of reporting in prospective studies that investigated antibiotic resistance
following antibiotic exposure in community-based individuals.
Methods: The quality of reporting of prospective studies (17 randomised trials, eight cohort studies) identified in
a systematic review of the relationship between antibiotic use and resistance were assessed independently by
two researchers using checklists (one for trials, one for cohort studies) developed from existing reporting guidelines for
these designs and this field.
Results: The mean percentage (SD, minimum-maximum) of mandatory items that were adequately described by the
included studies was 59% for trials (14%, 36–84%) and 52% for cohort studies (17%, 13–70%). Most studies adequately
described the study background and rationale, the type, combination, and duration of the antibiotic intervention, and
the sampling procedures followed to isolate resistant bacteria. Most studies did not report the incident numbers of
resistant and susceptible isolates analysed at each time point. Blinding and sample size calculation was inadequately
reported in almost half of the trials and all cohort studies.
Conclusions: The quality of reporting in prospective studies investigating the association between antibiotic exposure
in the community and isolation of resistance isolates is variable. Some details were missing in more than half of the
studies, which precludes a complete risk of bias assessment and accurate interpretation and synthesis of results.
Keywords: Antibiotic resistance, Quality of reporting, Primary care
Background
Antibiotic resistance is a global public health concern,
threatening lives by jeopardising successful treatment of a
vast range of bacterial infections [1, 2]. It is estimated that
10 million people may die in 2050 because of resistance
[3]. Antibiotic prescribing levels in primary care are high
[4, 5], even though for many of the conditions for which
they are prescribed (such as acute respiratory infections),
antibiotics provide minimal benefits and these may not be
outweighed by the harms of their use [6–10].
Antibiotic use drives resistance [11–13] and there is
some indication that resistance decays over time [13].
Knowledge about the association between antibiotic use,
the development of resistance, and timeframes of potential
decay is important for informing public health messages,
antibiotic resistance campaigns, and clinician training.
However, evidence syntheses investigating the relationship
between antibiotic exposure and the development and
decay of resistance have been limited to two systematic re-
views that have included mostly studies with retrospective
designs [11, 12]. Understanding the association between
antibiotic exposure and isolation of resistance bacteria is
best informed by prospective study designs. Such designs
offer better opportunities to control for confounding
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factors, including more precise timeframes of the duration
between antibiotic exposure and isolation of resistance
bacteria, which helps to avoid the uncertainty that is im-
plicit in ‘time-until’ periods that are dictated by retrospect-
ive designs. As global concern about resistance increases,
an increasing number of prospective studies investigating
this issue are being conducted.
However, to provide interpretable evidence and enable
complete risk of bias assessment, these studies need to be
reported clearly and comprehensively. There are charac-
teristics of studies that measure antibiotic exposure and
resistance that are not adequately captured by existing
reporting checklists and researchers may not have ad-
equate awareness of these issues and guidance about how
to report such studies. We are not aware of any studies
that have examined the quality of reporting of prospective
studies about antibiotic use and resistance. We aimed to
assess the completeness of reporting of prospective pri-
mary studies that examined antibiotic use and resistance.
Method
Selection of included studies
Studies were included in this study if they had been
identified as part of a recently published systematic re-
view that assessed the extent of bacterial resistance in
individuals caused by antibiotic use in primary care, and
the rate of decay of resistance [13].
Full details of the systematic review search are avail-
able elsewhere [13]. Briefly, we searched PubMed,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials from inception until the first week of May
2017, using MeSH terms, keywords, and forward and
backward citation searches. We included randomised
controlled trials and prospective cohort studies that
compared antibiotic-exposed patients in the community
against controls. Our outcome was the prevalence of re-
sistance bacteria over time.
Assessment of the quality of reporting of included
studies
For the present study, we developed two assessment
checklists (one for trials and one for prospective cohort
studies), based on existing reporting guidelines relevant to
these study designs and this field. For trials, the relevant
guideline was the Consolidated Standards of Reporting
Trials (CONSORT) statement [14]; for cohort studies, the
relevant guidelines were Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) [15]
and its extension for optimising reporting of epidemio-
logical studies in Antimicrobial Stewardship (STRO-
BE-AMS) [16]. Additional reporting recommendations
that are relevant to both study types include the Template
for Intervention Description and Replication (TIDieR
[17]) items and those specific to resistance reporting in
systematic reviews of antibiotic interventions [18].
Informed by our experience from completing the sys-
tematic review, several items necessary for the accurate
interpretation of results were added to the checklists.
The resultant checklists were piloted with four epidemi-
ologists and four antibiotic resistance researchers who
used them to assess the quality of reporting of a small
number of eligible studies. Following this, minor modifi-
cations were made to the grouping of the items, and the
explanatory wording of some of the additional items.
The final version of trial checklist had 89 items and the
cohort checklist had 81 items.
Two researchers (MB and AMS) then used the
checklists to independently assess the quality of
reporting of each included study. Each item was rated
‘Yes’ (if the study adequately described the item), ‘No’
(if it did not), or ‘Not applicable’. Agreement between
assessors was reached through discussion after small
batches of five studies were rated, and discrepancies
resolved through discussion with a third researcher
(TH or CDM). We did not calculate the agreement
between the two assessors. The complete checklists
with item descriptions and the source of each item
are available in Additional files 1 and 2.
Data analysis
Data were analysed using Microsoft Excel® 2016 (Micro-
soft, Redmond, WA, USA) and descriptive statistics were
calculated.
Results
The sample of articles consisted of 17 randomised
controlled trials and eight prospective cohort studies. The
trials primarily assessed the risk of isolation of post-treat-
ment carriage of resistant bacteria. They were published
from 1982 to 2016 and conducted in ten countries. The
cohort studies assessed changes in resistance patterns be-
fore and after antibiotic use. They were published from
1988 to 2008 and from seven countries (the full list of in-
cluded articles is shown in Additional file 3).
Completeness of reporting - trials
For the 17 trials, 70 mandatory items and an additional
19 ‘if applicable’ items were scored. Twelve (17%)
mandatory items were reported by all trials; one item
(describing other organisms susceptible to the exposed
antimicrobial or same class) was not reported by any tri-
als. The mean percentage (SD, minimum-maximum) of
the mandatory items that were adequately described by
the trials was 59% (14%, 36–84%) (see Fig. 1). Add-
itional file 4 shows the percentages of trials that ad-
equately described each item including the ‘if applicable’
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Fig. 1 Quality of reporting, percentage of RCTs meeting each item (studies = 17, mandatory items = 70). RCT randomised comtrolled trial
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items and Additional file 5 shows the percentage of
items adequately described by each trial.
The items that were most commonly reported include
those about: study background (all trials provided the
study rationale and described any previous in vivo and/
or in vitro studies); intervention (most trials adequately
described the type of antibiotics, duration and dose); and
sampling (almost all trials adequately reported the sam-
pling procedures followed for isolating resistant isolates
including the site, number of samples per person, and
sampling period).
Items that were poorly reported by many trials include
those describing the sample size, randomisation, blind-
ing, and the results. Almost half of the trials reported
the sample size determination, and more than half of the
trials poorly described the methods used for randomisa-
tion and allocation (including the person(s) responsible
for generating the random allocation sequence, and the
steps taken to conceal the randomisation sequence).
Blinding reporting was incomplete in almost half of the
trials and only one study reported blinding of microbiol-
ogists to the time of sampling. Many items describing
the results were missing in the majority of the trials, in-
cluding key details such as: the numbers analysed at
nominated time points, particularly the number of iso-
lates susceptible to the intervention or comparator (if
applicable); and the number of participants with sterile
swabs (clean-catch swabs) or resistance/susceptibility
among other organisms (other than the index pathogen)
isolated from other body site (other than the system/site
of interest).
Completeness of reporting - cohort studies
In the eight cohort studies, 63 mandatory items and an
additional 19 ‘if applicable’ items were scored: seven
(11%) mandatory items were reported by all cohort stud-
ies; eight (13%) were not reported by any. The mean per-
centage (SD, minimum-maximum) of the mandatory
items that were adequately described by the studies was
52% (17%, 13– 70%) (see Fig. 2). Additional file 6 shows
the percentage of cohort studies that adequately de-
scribed each item including the ‘if applicable’ items and
Additional file 7 shows the percentage of items ad-
equately described by each study.
The items most commonly reported were those about
the: study background (most described specific objec-
tives and study rationale); outcome measures (most
defined each measure and reported when each was mea-
sured); and sampling (most studies adequately described
the sampling procedures used, including the site, num-
ber of samples per person, and sampling period).
Items that were poorly reported were those describing
the sample size, measurement and results. None of the
studies reported how their sample size was determined
and none reported if resistance was measured by an in-
dependent laboratory or if the microbiologists were
blinded. As with the trials, many key details about the
numbers analysed were missing, such as the number of
susceptible isolates to antibiotic exposure analysed at
each of the nominated time points, along with the resist-
ance/susceptibility among other organisms isolated from
another body site.
Discussion
The quality of reporting of prospective studies examin-
ing antibiotic use and resistance varied in this study.
Some aspects of the studies (such as the sampling proce-
dures used and rationale for the study) were described
in most, but some details were missing in many studies.
Some of the missing items, such as those about blinding
or the numbers analysed, are particularly important for
assessing a study’s risk of bias and interpreting its results
accurately.
Few studies reported the incident numbers of both re-
sistant and susceptible isolates analysed at each time
point (and for both the intervention and/or comparator
groups), and only one study reported the isolation of re-
sistant isolates from body sites other than the target site/
system. This may be as important to know as the resist-
ance in the originally infected site, from the point of
view of antibiotic resistance generation in the micro-
biome, and hence in the community at large. Similarly,
most studies only reported resistance to the class of
antibiotic used, although some studies also reported re-
sistance to other antibiotic classes – a possibly import-
ant omission because of induced co-resistance to
antibiotics from different classes [19].
Reporting of how and whether blinding occurred was
inadequate in almost half of the studies. Only one study
reported whether the microbiologist was blinded to the
time of sampling. Data on changes in resistance over
time could be biased if those responsible for measuring
resistance are not blinded to the time of sampling. As
with other aspects of methods reporting, if a study does
not describe a process, a reader cannot be sure if the
process did not occur or was just not reported. This un-
certainty impedes risk of bias assessment and decreases
the confidence in the reported results.
While describing a study with sufficient detail to en-
able replication and interpretation of results is good sci-
entific practice, many authors are not aware of all the
details that need to be reported to sufficiently describe a
study. To assist authors with comprehensively describing
studies, reporting guidelines have been developed. How-
ever, for our sample of included studies, the impact of
reporting guidelines would have been minimal, as most
(88%) of the included cohort studies were published be-
fore the release of the STROBE reporting guidelines
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Fig. 2 Quality of reporting, percentage of cohort studies meeting each item (studies = 8, mandatory items = 63)
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(and all before the STROBE-AMS publication), and all
but one of the included trials were published before
the 2010 CONSORT statement, although most (except
three) were published before the 1996 CONSORT
statement [20].
As our sample of studies is limited to those included
in a systematic review of antibiotic resistance in individ-
uals who were prescribed antibiotics in primary care,
this may limit the generalisability of results beyond this
setting. Additionally, the checklists used to assess the
studies were modified from existing checklists and in-
formed by the pragmatic experience of researchers
assessing and synthesising these types of studies – the
modified checklist have not been formally assessed.
However, a strength of this study is the independent as-
sessment of the included studies by two authors.
Conclusions
In this study of the reporting quality of prospective stud-
ies examining antibiotic use and resistance, just over half
of the mandatory checklist items were adequately de-
scribed for the randomised trials and cohort studies in-
cluded. Some items (such as the type, combination, and
duration of the antibiotic intervention, and the sampling
procedures used to isolate resistant bacteria) were ad-
equately described by most studies, whereas other details
(such as the incident numbers of resistant and suscep-
tible isolates analysed at each time point) were not de-
scribed by most. Improving the quality of reporting of
future studies that measure antibiotic resistance is ne-
cessary to aid accurate synthesis and interpretation of re-
sults. Better reporting may be facilitated by a reporting
checklist, which is created following the recommenda-
tions for developing reporting guidelines [21], that is,
specific to prospective studies of antibiotic use and re-
sistance. This will help to improve the quality of report-
ing available to the research community, clinicians, and
policy makers.
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